Am J Clin Oncol
Department of Radiation Oncology, City of Hope Medical Center, Duarte, CA 91010, USA.
Published: October 2011
Objectives: To categorize sites of recurrence of retroperitoneal sarcomas (RPS) and correlate to clinical treatment volumes of postoperative radiation therapy (PORT) with or without intraoperative radiation therapy (IORT).
Methods: A retrospective review of patients with RPS who received PORT between 1990 and 2008 was done. Tumor recurrences were subdivided as local tumor bed, regional adjacent retroperitoneal fascial tissues, peritoneal diffuse seeding, and distant metastases.
Results: PORT was given to 33 patients, 20 of whom also received IORT. Local recurrences appeared in 4 (12%) cases. Regional recurrences appeared in 8 (26%) cases, including 5 with in-field recurrence and 3 with edge-of-field recurrence. Edge-of-field recurrences developed in 3 of 11 (27%) patients whose clinical presentation was local recurrence compared with none of 20 patients whose clinical presentation was a primary tumor (P=0.037). Late grades 3 to 4 gastrointestinal toxicities appeared in 1 of 10 (10%) patients who received intensity-modulated radiation therapy (IMRT) with a minimum 15-month follow-up compared with 4 of 15 (27%) patients who received standard RT.
Conclusions: Use of techniques such as IORT and IMRT can deliver a dose of approximately 60 Gy to the tumor bed and 44 to 51 Gy to the surrounding retroperitoneal fascial planes. Acute and late gastrointestinal toxicities were less frequent with IMRT compared with conventional PORT with IORT. These results may provide the basis for comparison of various adjuvant therapy strategies for RPS. As radiation therapy is a loco-regional treatment, results should be reported by tumor recurrence subtypes of local, regional, peritoneal, and distant.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/COC.0b013e3181f4796d | DOI Listing |
J Neurosurg
March 2025
1Department of Neurosurgery, Medical University of Vienna.
Objective: Recent treatment guidelines state that in patients with asymptomatic brain metastases (BMs), local treatment can be delayed until there is evidence of intracranial progression. However, while patients with symptomatic BMs typically require dexamethasone treatment, recent data on the impact of this medication on the outcomes of patients with BMs are lacking. Therefore, the authors conducted a prospective study to evaluate concomitant dexamethasone treatment in a population of radiosurgically treated patients with BMs from non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFJBJS Case Connect
January 2025
Department of Orthopaedic Surgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Case: A 26-month-old child with spastic quadriplegic cerebral palsy, TPN dependence, laryngomalacia, and G6PD deficiency presented with right hip pain with no known recent trauma. Imaging revealed a slipped capital femoral epiphysis (SCFE). The patient underwent hip irrigation and debridement for potential septic arthritis, with SCFE stabilized using buried 2.
View Article and Find Full Text PDFCancer Rep (Hoboken)
March 2025
Department of Oncology, KU Leuven, Leuven, Belgium.
Background: CD19-directed chimeric antigen receptor T-cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal.
View Article and Find Full Text PDFRadiol Phys Technol
March 2025
Department of Radiological Technology, Asahikawa Medical University Hospital, 2-1-1-1, Midorigaoka Higashi, Asahikawa, Hokkaido, 078-8510, Japan.
This study aimed to survey technical variations in total body irradiation (TBI) across Japan. A web-based questionnaire investigating technical aspects (irradiation method, in vivo dosimetry, organ shielding, and boluses) of TBI was distributed via the authors' acquaintances in each region of Japan using snowball sampling, and 73 institutions responded. The data were collected from January to April 2024.
View Article and Find Full Text PDFBreast Cancer Res Treat
March 2025
Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287, Chang Huai Road, Bengbu, 233000, China.
Purpose: To evaluate the role of Postoperative Radiotherapy (PORT) in HER2-positive metastatic breast cancer (MBC) in the context of targeted therapy and clarify the subgroups that may benefit from PORT.
Methods: Clinical data of female patients with HER2-positive MBC from the surveillance, epidemiology, and end results (SEER) database for the years 2016-2020 were collected according to established inclusion and exclusion criteria. The impact of PORT on patient survival was assessed, and subgroup analyses were performed to identify populations with potential benefits from PORT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.